What Is Bacitracin?

Backtracin is a topical antibiotic derived from the bacterium Bacillus subtilis. It works by inhibiting bacterial cell wall synthesis, making it effective against a wide range of gram-positive bacteria. Bacitracin has been FDA-approved since the 1940s and remains one of the most widely used over-the-counter topical antibiotics in the US and Canada.

You'll find it in drugstore antibiotic ointments, often combined with neomycin and polymyxin B (the triple antibiotic ointment). It's designed for minor cuts, scrapes, burns, and skin infections. Bacitracin doesn't absorb systemically—it stays on the skin surface—which is why it's considered very safe with minimal side effects.

Evidence for Bacitracin

With 40 clinical trials in the literature, bacitracin has an extensive safety and efficacy record. Studies confirm it's effective for preventing infection in minor wounds and reducing healing time, and it's a standard recommendation in wound care guidelines across North America. The evidence grade is A, reflecting decades of consistent real-world use.

Regulatory Status

Backtracin is FDA-approved in the US, approved by Health Canada, and available over-the-counter without a prescription in both regions. It is not authorized by the EMA in Europe.

What Is Elagolix?

Elagolix is a gonadotropin-releasing hormone (GnRH) antagonist—a systemic oral medication that suppresses the pituitary-gonadal axis. It works by blocking GnRH signalling, which reduces circulating estrogen and progesterone levels. Elagolix was FDA-approved in 2018 for moderate to severe pain associated with endometriosis and is a prescription-only medication.

Unlike bacitracin, elagolix is absorbed into the bloodstream and has systemic hormonal effects. It's designed for people with endometriosis—a condition where tissue similar to the uterine lining grows outside the uterus, causing chronic pain.

Evidence for Elagolix

The Phase 3 trial program for elagolix enrolled over 800 women and demonstrated significant pain reduction compared to placebo, with 31 clinical trials supporting its development and approval. The evidence grade is A. Studies show elagolix reduces both dysmenorrhea (period pain) and non-menstrual pelvic pain in people with endometriosis.

Regulatory Status

Elagolix is FDA-approved in the US and approved by Health Canada. Like bacitracin, it is not authorized by the EMA in Europe. It requires a prescription and is typically covered by insurance for endometriosis when other treatments have failed.

Key Differences at a Glance

| Feature | Bacitracin | Elagolix | |---------|-----------|----------| | Class | Topical antibiotic | Systemic GnRH antagonist | | Route | Applied to skin | Oral tablet | | Primary use | Minor skin infections, wound care | Endometriosis pain | | Mechanism | Inhibits bacterial cell wall synthesis | Suppresses pituitary-gonadal axis | | Absorption | Topical only, no systemic absorption | Orally absorbed, systemic effects | | Side effects | Rare (local reactions) | More common (hot flashes, bone density concerns) | | Prescription required | No (OTC) | Yes | | Clinical trials | 40 | 31 | | Evidence grade | A | A | | FDA approval | Yes | Yes | | Health Canada | Yes | Yes | | EMA approval | No | No |

Mechanism: How They Work Differently

Backtracin and elagolix operate on completely different biological systems:

Bacitracin targets bacteria. It binds to lipid carriers in bacterial cell walls, preventing peptidoglycan cross-linking. This makes it bactericidal—it actively kills bacteria rather than just slowing their growth. Because it's a peptide antibiotic and doesn't penetrate skin deeply, it's ideal for surface-level infections.

Elagolix targets human hormonal signalling. As a competitive GnRH antagonist, it binds to GnRH receptors on pituitary gonadotrophs, suppressing the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This cascade reduces estrogen production, which is thought to reduce lesion growth and pain in endometriosis.

These mechanisms are so different that comparing them directly is a bit like comparing a screwdriver to a wrench—they solve different problems.

Who Should Use Each?

Bacitracin Is Right If You Have:

  • Minor cuts, scrapes, or abrasions at risk of infection
  • Small surgical wounds (post-procedure care)
  • Mild skin infections or irritation
  • Preference for OTC treatment without a doctor visit
  • Need for immediate, accessible wound care

Backitracin shines because it's inexpensive, readily available, and safe enough that generations have used it without significant issues. It's also suitable for children and doesn't interact with other medications because it's not absorbed systemically.

Elagolix Is Right If You Have:

  • Moderate to severe endometriosis-related pain
  • Failed or intolerant to other endometriosis treatments (e.g., NSAIDs, hormonal contraceptives, GnRH agonists like leuprolide)
  • Need for systemic pain relief beyond topical application
  • Access to a healthcare provider and prescription
  • Willingness to accept hormonal side effects for pain reduction

Elagolix requires more careful monitoring. Doctors typically prescribe it for 6–12 months and monitor bone density, given the estrogen-suppressive effects. It's not suitable for pregnant individuals or those planning pregnancy in the near term.

Safety & Side Effects

Bacitracin

Backitracin is remarkably safe. Local reactions—redness, itching, or mild rash—occur in fewer than 1% of users. True allergic reactions are rare. There are no systemic side effects because it doesn't enter the bloodstream. It can be used long-term on chronic wounds without concern.

Elagolix

Elagolix causes hormonal side effects because that's how it works. Common ones include hot flashes, night sweats, vaginal dryness, and mood changes. Clinical trials reported hot flashes in 28–32% of elagolix users versus 5–10% on placebo. Bone mineral density decreases, which is why treatment is usually limited to 24 months and requires baseline and periodic DEXA scans. The benefit-to-risk profile is favorable for endometriosis pain, but elagolix isn't taken lightly.

Cost & Accessibility

Bacitracin costs $5–$15 for a tube and is available at any pharmacy, drugstore, or supermarket without a prescription. It's typically not covered by insurance because it's OTC, but the out-of-pocket cost is negligible.

Elagolix is prescription-only and significantly more expensive—typically $300–$600 per month without insurance. Most insurance plans cover it for endometriosis when medically necessary, often with step-therapy requirements (meaning you try other treatments first). Patient assistance programs are available through the manufacturer.

Related Compounds

If you're exploring peptide and hormone-based treatments, you might also want to understand leuprolide, a GnRH agonist used for similar endometriosis indications (though with a different mechanism than elagolix), or goserelin, another hormone-modulating peptide. For topical infections, mupirocin is a modern alternative to bacitracin worth comparing.

The Bottom Line

Backitracin and elagolix are both FDA-approved, evidence-backed compounds—but they exist in entirely different therapeutic universes. Bacitracin is a topical antibiotic for everyday skin care; elagolix is a systemic hormonal therapy for a specific painful condition. Neither is "better"—they address different needs.

Choose bacitracin if you need simple, safe, inexpensive wound care. Choose elagolix only if you have endometriosis-related pain and have discussed the hormonal trade-offs with your healthcare provider. And remember: elagolix requires a prescription and ongoing medical oversight, while bacitracin is a grab-and-go staple.

For more on how GnRH antagonists work, or to learn about the difference between topical and systemic delivery, check our glossary.